Estrella Immunopharma Reports 100% Complete Response in Second Dose Cohort of EB103 Trial for Advanced B-Cell Non-Hodgkin’s Lymphoma
According to Towards Healthcare Study, Estrella Immunopharma, Inc., a clinical-stage biopharmaceutical innovator developing CD19 and CD22-targeted ARTEMIS® T-cell therapies for […]






